The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and feasibility of consolidation pembrolizumab following concurrent chemoradiation for unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN14-179.
 
Greg Andrew Durm
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Cynthia Johnson
Employment - Lilly (I)
Stock and Other Ownership Interests - Lilly (I)
 
Shadia Ibrahim Jalal
Research Funding - AstraZeneca/MedImmune
 
Ahad Ali Sadiq
Speakers' Bureau - AstraZeneca
 
Salma Jabbour
Consulting or Advisory Role - Elekta
Research Funding - Merck (Inst)
 
Robin Zon
Consulting or Advisory Role - MedPro Specialty Advisory Board
Research Funding - Agendia (Inst); Amgen (Inst)
Other Relationship - MedPro Specialty Advisory Board
 
Goetz H. Kloecker
Honoraria - Bristol-Myers Squibb; Celgene; Lilly; Merck
Consulting or Advisory Role - Lilly
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Lilly; Merck
Research Funding - Bristol-Myers Squibb
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; ARIAD; Astellas Pharma; Boehringer Ingelheim; Euclises; Nektar
Research Funding - Adaptimmune (Inst); ARIAD (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Xcovery (Inst)
 
William B. Fisher
No Relationships to Disclose
 
Nasser H. Hanna
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst)